Johnson & Johnson Moves to Battle Coronavirus
January 29 2020 - 09:42AM
Dow Jones News
By Chris Wack
Johnson & Johnson (JNJ) said Wednesday it is mobilizing
resources at its Janssen Pharmaceutical Cos. to launch a
multi-pronged response to the novel coronavirus outbreak, also
known as 2019-nCoV.
The company said it has begun efforts to develop a vaccine
candidate against 2019-nCoV and broadly collaborate with others to
screen a library of antiviral therapies. The company said
identifying compounds with antiviral activity against 2019-nCoV may
contribute to providing immediate relief to the current
outbreak.
Johnson & Johnson said the vaccine program will use
Janssen's AdVac and PER.C6 technologies, which will provide the
ability to rapidly upscale production of the optimal vaccine
candidate. The company used the same technologies in the
development and manufacturing of Janssen's investigational Ebola
vaccine, which is currently deployed in the Democratic Republic of
the Congo and Rwanda.
Janssen has donated 300 boxes of its HIV medication Prezcobix
darunavir/cobicistat to the Shanghai Public Health Clinical Center
and Zhongnan Hospital of Wuhan University for use in research to
support efforts in finding a solution against the 2019-nCoV.
Another 50 boxes have been provided to the Chinese Center for
Disease Control and Prevention for laboratory-based
investigations.
The World Health Organization has now confirmed cases of
2019-nCoV across mainland China, with cases also confirmed in
countries and territories worldwide, including Australia, Cambodia,
Hong Kong, Japan, Thailand, the U.S. and Vietnam.
Write to Chris Wack at chris.wack@wsj.com
(END) Dow Jones Newswires
January 29, 2020 09:27 ET (14:27 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Feb 2024 to Mar 2024
Johnson and Johnson (NYSE:JNJ)
Historical Stock Chart
From Mar 2023 to Mar 2024